Trials / Completed
CompletedNCT00149916
Follow-up Study of Safety of Enteric-coated Mycophenolate Sodium in Patients Who Successfully Completed Study CERL080A0107
Multicenter, Open-label Follow-up Study on the Safety of Enteric-coated Mycophenolate Sodium in Renal Transplant Patients.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 139 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- —
Summary
Aim of study is to provide safety and tolerability data on enteric-coated mycophenolate sodium in regard to adverse events, serious adverse events and patient and graft survival. After successful completion of the study CERL080A0107 study, patients could continue to receive enteric-coated mycophenolate sodium.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mycophenolate sodium (enteric coated) |
Timeline
- Start date
- 2000-04-01
- Primary completion
- 2004-04-01
- First posted
- 2005-09-08
- Last updated
- 2011-11-02
Source: ClinicalTrials.gov record NCT00149916. Inclusion in this directory is not an endorsement.